Precision for Medicine is a Bethesda, Maryland–based specialty services company that supports pharmaceutical and life sciences companies through product development and commercialization. Led by co‑founder and executive chairman Ethan Leder, the company provides an integrated infrastructure to help clients demonstrate economic value, validate outcomes, and build differentiation within the healthcare marketplace. It applies science, technology, expertise and project execution to advance patient‑centric solutions from discovery through commercialization. The company received a $75M investment from TPG Growth. It will use the proceeds to grow both organically and via acquisitions. Precision for Medicine provides services and infrastructure to support life science companies developing new products, including regulatory sciences, clinical development, commercialization, and product strategy expertise. The company is building a comprehensive platform of specialized development and commercialization services intended to speed approval, reduce costs, and optimize market launch. It also offers next‑generation bioservices such as biorepository, sample management, and cellular products from facilities in Frederick and Gaithersburg, MD. Formed in 2012 and based in Chevy Chase, MD, Precision employs over 130 people. The company secured a $150M private equity financing and intends to use the proceeds for acquisitions and development. Backers in the financing included Oak Investment Partners, J.H. Whitney and Company, and Precision’s co‑founders Ethan D. Leder and Mark P. Clein.

Total raised

$225M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2015